Synlogic, Inc. (SYBX) News
Filter SYBX News Items
SYBX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SYBX News Highlights
- SYBX's 30 day story count now stands at 2.
- Over the past 20 days, the trend for SYBX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC and LAB are the most mentioned tickers in articles about SYBX.
Latest SYBX News From Around the Web
Below are the latest news stories about SYNLOGIC INC that investors may wish to consider to help them evaluate SYBX as an investment opportunity.
Synlogic Announces Contract with the Air Force Research Lab- Selection of Synlogic reflects Company’s leadership in process development and manufacturing of therapeutics based on synthetic biology -CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that it has entered into an approximately $1 million subcontract under an Air Force Research Lab (AFRL) prime contract to |
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU), includin |
Sidoti Events, LLC’s Virtual November Micro-Cap ConferenceNEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November ... |
Synlogic Inc (SYBX) Reports Q3 2023 Financial Results with Extended Cash Runway and Clinical ...Key Developments and Financial Highlights for Investors |
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 - - Progress of the Synpheny-3 pivotal trial in phenylketonuria (PKU) supports enrollment completion in 2024, with top-line data in the first half of 2025 - - Company received Fast Track Designation from the FDA for labafenogene marselecobac (SYNB1934) as a potential treatment for PKU - CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Synlo |
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche CollaborationCAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced today that it has achieved its third pre-specified research milestone and earned a third milestone payment of $2.5 million due under its collaboration agreement with Roche for the research and pre-clinical development of a Synthetic Biotic for the treatment of |
Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseSynlogic, Inc. (SYBX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Synlogic Announces Closing of $21.0 Million Underwritten Public OfferingCAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the closing of its previously announced underwritten public offering. The offering consisted of 7,394,363 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase up to 7,394,36 |
Synlogic Announces Pricing of $21.0 Million Underwritten Public OfferingCAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the pricing of an underwritten public offering of (i) 7,394,363 shares of common stock (or common stock equivalents in lieu thereof) and (ii) accompanying common warrants to purchase up to an aggregate of 7,394,363 shares of common stock. The combined e |
META Stock Alert: 9 Takeaways From Meta Connect 2023Meta Platforms stock is a hot topic among traders on Thursday following updates from the company's Meta Connect 2023 event. |